Cyclacel Pharmaceuticals, Inc. (CYCC)

Cyclacel Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3.14	3.38	18.35	36.56	33.41
Cash & Short-Term Investments	3.14	3.38	18.35	36.56	33.41
Cash Growth	-7.13%	-81.59%	-49.82%	9.44%	181.08%
Other Receivables	-	2.93	4.66	3.73	1.31
Receivables	-	2.93	4.66	3.73	1.31
Prepaid Expenses	0.24	0.79	0.98	0.58	0.68
Other Current Assets	0.3	0.34	0.43	0.08	0.07
Total Current Assets	3.67	7.44	24.41	40.94	35.47
Property, Plant & Equipment	0.01	0.1	0.17	0.09	1.33
Other Long-Term Assets	0.41	1.26	3.47	2.1	-
Total Assets	4.09	8.81	28.05	43.14	36.8
Accounts Payable	4.6	3.54	2.56	2.12	0.51
Accrued Expenses	1.39	4.24	4.62	3.04	1.11
Other Current Liabilities	0.28	0.38	0.33	0.26	0.87
Total Current Liabilities	6.27	8.16	7.51	5.41	2.49
Long-Term Leases	-	0.04	0.11	0.03	1.06
Other Long-Term Liabilities	-	-	4.49	-	-
Total Liabilities	6.27	8.2	12.11	5.44	3.54
Common Stock	0.01	0	0	0.01	0.01
Additional Paid-In Capital	438.2	429.8	422.98	422.96	400.07
Retained Earnings	-439.49	-428.28	-405.73	-384.53	-366.07
Comprehensive Income & Other	-0.89	-0.91	-1.32	-0.75	-0.75
Shareholders' Equity	-2.17	0.61	15.94	37.69	33.26
Total Liabilities & Equity	4.09	8.81	28.05	43.14	36.8
Total Debt	-	0.04	0.11	0.03	1.06
Net Cash (Debt)	3.14	3.34	18.24	36.53	32.35
Net Cash Growth	-6.11%	-81.68%	-50.07%	12.92%	202.50%
Net Cash Per Share	0.59	3.93	24.31	61.39	133.55
Filing Date Shares Outstanding	207.34	1.32	0.84	0.67	0.47
Total Common Shares Outstanding	8.86	1.06	0.84	0.67	0.42
Working Capital	-2.59	-0.72	16.9	35.53	32.98
Book Value Per Share	-0.25	0.57	19.07	56.58	79.86
Tangible Book Value	-2.17	0.61	15.94	37.69	33.26
Tangible Book Value Per Share	-0.25	0.57	19.07	56.58	79.86
Machinery	0.42	0.42	0.41	0.42	0.58
Leasehold Improvements	0.01	0.01	0.01	0.01	0.41

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q